Therapeutic Options to Covid-19: A Perspective on Pharmacological Properties and Safety | Chapter 3 | Novel Aspects on Pharmaceutical Research Vol. 7

 The aim concerning this chapter is to resolve therapeutic alternatives to try Covid-19, that combine antiviral adding an antagonistic-inflammatory drug, procuring efficiency and security.Coronavirus ailment 2019 (COVID-19) is a serious threat to community health and is in urgent need of specific drugs. There are no pieces of advice for the pharmacological management of COVID-19 ailment, although a number of cures are being evaluated daily investigation of the best healing approach. Some antiviral medications, such as danoprevir, favipiravir, darunavir, nelfinavir, remdesivir, umifenovir, and the alliance of lopinavir and ritonavir, have been judged thus far. Others are drugs targeting instigative mediators such as meplazumab, siltuximab, tocilizumab, azithromycin and corticosteroids. Also included in this place array of tested drugs are those accompanying pleiotropic actions against SARS-CoV-2 infection like chloroquine/hydroxychloroquine, ivermectin and nitazoxanide, supposed as inhibitors of several phases of bug life cycle. When SARS-CoV-2 contamination is identified, it is important to start a situation plan based on available antiviral substitutes, properly controlled in a suitable medical scene. We recommend that medications that mark inflammatory mediators be overthrown by an enemy into consideration in addition to antiviral alternatives.

Author(s) Details:

Omar F. Carrasco ,
Department of Pharmacology, Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico.

Jesús Enrique Morales-Ríos,
Department of Pharmacology, Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico.

Hugo Juárez Olguín,
Department of Pharmacology, Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico and Laboratory of Pharmacology, Instituto Nacional de Pediatria, Mexico City, Mexico.

Monica Punzo Soto,
Laboratory of Pharmacology, Instituto Nacional de Pediatria, Mexico City, Mexico.

Please see the link here: https://stm.bookpi.org/NAPR-V7/article/view/11432